When 10,000 doctors stood up and cheered for a cancer drug — America’s innovation machine made it possible
You might have seen, in early June, more than 10,000 oncologists and drug developers gave a standing ovation mid-presentation. The slide that moved the room showed survival curves for Revolution Medicine’s daraxonrasib. For the first time, a drug showed a path to beating pancreatic cancer, nearly doubling survival.
- ▪You might have seen, in early June, more than 10,000 oncologists and drug developers gave a standing ovation mid-presentation.
- ▪The slide that moved the room showed survival curves for Revolution Medicine’s daraxonrasib.
- ▪For the first time, a drug showed a path to beating pancreatic cancer, nearly doubling survival.
Fortune files mainly under business. We currently carry 643 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Fortune |
| Canonical URL | https://fortune.com/2026/07/25/pancreatic-cancer-drug-innovation-treadmill-policy-risk/ |
| Publication time | Sat, 25 Jul 2026 11:30:00 +0000 |
| Retrieval time | 2026-07-25T11:42:10.800Z |
| Last seen | 2026-07-25T11:42:10.800Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | AOPbNQcNyNYo |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
You might have seen, in early June, more than 10,000 oncologists and drug developers gave a standing ovation mid-presentation. The slide that moved the room showed survival curves for Revolution Medicine’s daraxonrasib. For the first time, a drug showed a path to beating pancreatic cancer, nearly doubling survival. Thanks to social media, millions more shared that moment.Recommended Video Over the last half-dozen years of my 25-year career in biotech, I’ve enjoyed more and more moments like this. The vast majority have been thanks to U.S. leadership in drug innovation. But we are at an important crossroads. American patients face high healthcare costs at home, while the rise of China and AI adds new anxieties.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fortune.
Discussion
0 commentsMore from Fortune
